Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 The 10 Most Frequent AEs (Safety Population)

From: Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis

  Lumiracoxib 100 mg o.d. (n = 755) Lumiracoxib 100 mg b.i.d. (n = 1,519) Celecoxib 200 mg o.d. (n = 758)
Headache 82 (10.9) 174 (11.5) 82 (10.8)
Nasopharyngitis 80 (10.6) 141 (9.3) 75 (9.9)
Back pain 46 (6.1) 87 (5.7) 52 (6.9)
Arthralgia 53 (7.0) 82 (5.4) 41 (5.4)
Abdominal pain upper 42 (5.6) 88 (5.8) 35 (4.6)
Upper respiratory tract infection 36 (4.8) 86 (5.7) 43 (5.7)
Dyspepsia 38 (5.0) 85 (5.6) 39 (5.1)
Urinary tract infection 38 (5.0) 75 (4.9) 24 (3.2)
Sinusitis 21 (2.8) 58 (3.8) 34 (4.5)
Influenza 30 (4.0) 53 (3.5) 28 (3.7)
  1. o.d. = once daily; b.i.d. = twice daily.